KR102652879B1 - 감염으로 인한 것이 아닌 자극의 치료를 위한 점안액 - Google Patents
감염으로 인한 것이 아닌 자극의 치료를 위한 점안액 Download PDFInfo
- Publication number
- KR102652879B1 KR102652879B1 KR1020197029124A KR20197029124A KR102652879B1 KR 102652879 B1 KR102652879 B1 KR 102652879B1 KR 1020197029124 A KR1020197029124 A KR 1020197029124A KR 20197029124 A KR20197029124 A KR 20197029124A KR 102652879 B1 KR102652879 B1 KR 102652879B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- pharmaceutical composition
- treatment
- irritation
- glycerol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 57
- 230000007794 irritation Effects 0.000 title claims abstract description 46
- 208000015181 infectious disease Diseases 0.000 title abstract description 8
- 239000003889 eye drop Substances 0.000 title description 18
- 229940012356 eye drops Drugs 0.000 title description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 150
- 238000000034 method Methods 0.000 claims abstract description 61
- 210000002919 epithelial cell Anatomy 0.000 claims abstract description 41
- 238000010186 staining Methods 0.000 claims abstract description 17
- KZMRYBLIGYQPPP-UHFFFAOYSA-M 3-[[4-[(2-chlorophenyl)-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]cyclohexa-2,5-dien-1-ylidene]methyl]-n-ethylanilino]methyl]benzenesulfonate Chemical compound C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)Cl)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 KZMRYBLIGYQPPP-UHFFFAOYSA-M 0.000 claims abstract description 11
- 239000013543 active substance Substances 0.000 claims abstract description 7
- 239000007864 aqueous solution Substances 0.000 claims description 38
- 210000004027 cell Anatomy 0.000 claims description 20
- 229920002125 Sokalan® Polymers 0.000 claims description 12
- 230000006378 damage Effects 0.000 claims description 11
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 10
- 239000003755 preservative agent Substances 0.000 claims description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 9
- 229960001631 carbomer Drugs 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 230000009849 deactivation Effects 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 3
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 3
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 3
- 239000006172 buffering agent Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 46
- 239000000203 mixture Substances 0.000 abstract description 20
- 230000002265 prevention Effects 0.000 abstract description 13
- 229920006158 high molecular weight polymer Polymers 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 26
- 229920000642 polymer Polymers 0.000 description 19
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000000638 stimulation Effects 0.000 description 10
- 230000005779 cell damage Effects 0.000 description 9
- 125000000129 anionic group Chemical group 0.000 description 8
- 208000037887 cell injury Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 208000023715 Ocular surface disease Diseases 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 206010013774 Dry eye Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- 206010056476 Corneal irritation Diseases 0.000 description 2
- 102100028314 Filaggrin Human genes 0.000 description 2
- 101710088660 Filaggrin Proteins 0.000 description 2
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 2
- 102000003940 Occludin Human genes 0.000 description 2
- 108090000304 Occludin Proteins 0.000 description 2
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000607 artificial tear Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 229940014041 hyaluronate Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 108010033564 involucrin Proteins 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 238000012148 non-surgical treatment Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 229930187593 rose bengal Natural products 0.000 description 2
- AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 description 2
- 229940081623 rose bengal Drugs 0.000 description 2
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000004489 tear production Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- AQQSXKSWTNWXKR-UHFFFAOYSA-N 2-(2-phenylphenanthro[9,10-d]imidazol-3-yl)acetic acid Chemical compound C1(=CC=CC=C1)C1=NC2=C(N1CC(=O)O)C1=CC=CC=C1C=1C=CC=CC=12 AQQSXKSWTNWXKR-UHFFFAOYSA-N 0.000 description 1
- 206010010725 Conjunctival irritation Diseases 0.000 description 1
- 108010072220 Cyclophilin A Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 101001067833 Homo sapiens Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010023642 Lacrimation decreased Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 201000000009 conjunctivochalasis Diseases 0.000 description 1
- 208000021921 corneal disease Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 102000007236 involucrin Human genes 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762467139P | 2017-03-05 | 2017-03-05 | |
| US62/467,139 | 2017-03-05 | ||
| PCT/IL2018/050184 WO2018163151A1 (en) | 2017-03-05 | 2018-02-19 | Eye drops for treatment of irritation not due to infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190129065A KR20190129065A (ko) | 2019-11-19 |
| KR102652879B1 true KR102652879B1 (ko) | 2024-03-29 |
Family
ID=61656085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197029124A Active KR102652879B1 (ko) | 2017-03-05 | 2018-02-19 | 감염으로 인한 것이 아닌 자극의 치료를 위한 점안액 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11033513B2 (enExample) |
| EP (2) | EP3592339B1 (enExample) |
| JP (1) | JP7258778B2 (enExample) |
| KR (1) | KR102652879B1 (enExample) |
| CN (1) | CN110891555B (enExample) |
| AU (1) | AU2018230262B2 (enExample) |
| BR (1) | BR112019018367A2 (enExample) |
| CA (1) | CA3055523C (enExample) |
| ES (1) | ES3036888T3 (enExample) |
| IL (1) | IL269133B2 (enExample) |
| MX (1) | MX388961B (enExample) |
| PL (1) | PL3592339T3 (enExample) |
| RU (1) | RU2019130955A (enExample) |
| WO (1) | WO2018163151A1 (enExample) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006123324A1 (en) * | 2005-05-16 | 2006-11-23 | Resdevco Research And Development Co. Ltd., | Topical compositions |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL80298A (en) | 1986-10-14 | 1993-01-31 | Res & Dev Co Ltd | Eye drops |
| US5895645A (en) * | 1995-01-31 | 1999-04-20 | Bausch & Lomb Incorporated | Opthalmic solution for artificial tears |
| JP3093661B2 (ja) * | 1995-10-12 | 2000-10-03 | 大塚製薬株式会社 | 眼疾患治療剤 |
| AR004214A1 (es) * | 1995-10-12 | 1998-11-04 | Otsuka Pharma Co Ltd | Una preparación de gotas oftálmicas para la cura de enfermedades oftálmicas |
| IL120005A (en) * | 1997-01-14 | 2000-08-31 | Ramot University Authority Of | Pharmaceutical compositions for the treatment of the eye |
| US5800807A (en) * | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| DE102005055275A1 (de) | 2005-11-17 | 2007-05-24 | Ursapharm Arzneimittel Gmbh & Co. Kg | Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung |
| IL212725A (en) * | 2011-05-05 | 2016-06-30 | Resdevco Res And Dev Co | Glycerol Preparation for Non-surgical Conjunctivochalysis |
| KR102107471B1 (ko) | 2011-11-24 | 2020-05-07 | 토요 슈가 리파이닝 컴퍼니 리미티드 | 각결막 보호제 또는 각결막 장해 억제제 |
| US9278132B2 (en) | 2012-02-13 | 2016-03-08 | Bausch & Lomb Incorporated | Ophthalmic pharmaceutical compositions and methods of making and using same |
-
2018
- 2018-02-19 JP JP2019568840A patent/JP7258778B2/ja active Active
- 2018-02-19 PL PL18711415.2T patent/PL3592339T3/pl unknown
- 2018-02-19 EP EP18711415.2A patent/EP3592339B1/en active Active
- 2018-02-19 KR KR1020197029124A patent/KR102652879B1/ko active Active
- 2018-02-19 CN CN201880029944.8A patent/CN110891555B/zh active Active
- 2018-02-19 BR BR112019018367A patent/BR112019018367A2/pt not_active Application Discontinuation
- 2018-02-19 ES ES18711415T patent/ES3036888T3/es active Active
- 2018-02-19 WO PCT/IL2018/050184 patent/WO2018163151A1/en not_active Ceased
- 2018-02-19 IL IL269133A patent/IL269133B2/en unknown
- 2018-02-19 MX MX2019010471A patent/MX388961B/es unknown
- 2018-02-19 AU AU2018230262A patent/AU2018230262B2/en active Active
- 2018-02-19 RU RU2019130955A patent/RU2019130955A/ru unknown
- 2018-02-19 CA CA3055523A patent/CA3055523C/en active Active
- 2018-02-19 EP EP24173992.9A patent/EP4385565A3/en active Pending
-
2019
- 2019-09-04 US US16/560,084 patent/US11033513B2/en active Active
-
2021
- 2021-03-03 US US17/191,191 patent/US11426361B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006123324A1 (en) * | 2005-05-16 | 2006-11-23 | Resdevco Research And Development Co. Ltd., | Topical compositions |
Non-Patent Citations (1)
| Title |
|---|
| Journal of ocular pharmacology and therapeutics. Vol. 28(5), pp 473~478(2012년) |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3055523A1 (en) | 2018-09-13 |
| EP4385565A2 (en) | 2024-06-19 |
| KR20190129065A (ko) | 2019-11-19 |
| EP3592339A1 (en) | 2020-01-15 |
| JP7258778B2 (ja) | 2023-04-17 |
| US20190388361A1 (en) | 2019-12-26 |
| CN110891555A (zh) | 2020-03-17 |
| US11426361B2 (en) | 2022-08-30 |
| AU2018230262B2 (en) | 2024-01-18 |
| CA3055523C (en) | 2024-10-01 |
| EP3592339C0 (en) | 2025-04-30 |
| IL269133B1 (en) | 2024-05-01 |
| MX388961B (es) | 2025-03-20 |
| EP3592339B1 (en) | 2025-04-30 |
| EP4385565A3 (en) | 2024-08-21 |
| US20210186892A1 (en) | 2021-06-24 |
| AU2018230262A1 (en) | 2019-09-26 |
| WO2018163151A1 (en) | 2018-09-13 |
| PL3592339T3 (pl) | 2025-09-01 |
| RU2019130955A3 (enExample) | 2021-06-24 |
| BR112019018367A2 (pt) | 2020-04-07 |
| US11033513B2 (en) | 2021-06-15 |
| RU2019130955A (ru) | 2021-04-07 |
| CN110891555B (zh) | 2023-12-26 |
| JP2020509092A (ja) | 2020-03-26 |
| MX2019010471A (es) | 2020-02-12 |
| IL269133A (en) | 2019-11-28 |
| IL269133B2 (en) | 2024-09-01 |
| ES3036888T3 (en) | 2025-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2687275C2 (ru) | Слезозаменитель, содержащий гиалуронат натрия и карбоксиметилцеллюлозу | |
| AU2011282683B2 (en) | Preservative free brimonidine and timolol solutions | |
| IL182532A (en) | Topical ophthalmic composition and an artificial tear for the treatment of dry eye and use of the composition or the artificial tear for the manufacture of a medicament | |
| JP2005513106A (ja) | ヘパリンを保有する眼薬剤 | |
| JP2022537139A (ja) | 抗老眼効果を増強するためのカルバコール－ブリモニジン製剤 | |
| KR101412776B1 (ko) | 각결막염 치료용 점안제 조성물 및 이의 제조 방법 | |
| CN110913867B (zh) | 热凝胶化人工泪液 | |
| WO2009088119A1 (en) | Composition for preventing or treating dry eye syndrome comprising poly-gamma-glutamic acid | |
| KR102652879B1 (ko) | 감염으로 인한 것이 아닌 자극의 치료를 위한 점안액 | |
| US8912166B2 (en) | Eye drops for treatment of conjunctivochalasis | |
| US20250360185A1 (en) | Compositions comprising pedf-derived short peptides for the treatment of dry eye diseases | |
| RU2836815C1 (ru) | Офтальмологические композиции для местного применения на ксантановой основе с сокращенным режимом дозирования | |
| US20190151352A1 (en) | Ophthalmic composition comprising a synergistic combination of glycogen and hyaluronic acid or a salt thereof | |
| WO2023048174A1 (ja) | 角膜疾患治療剤 | |
| TW202320835A (zh) | 用於治療或抑制細胞損失之組氨素組合及方法 | |
| WO2021156856A1 (en) | Topical opthalmological composition containing hyaluronate and taurine having non-newtonian rheological properties | |
| CN118103055A (zh) | 组氨素组合和治疗或抑制细胞损失的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20191002 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210218 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20221102 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230613 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20240124 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20240326 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20240326 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |